Soleno Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SLNO Nasdaq 2836 soleno.life

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Soleno Therapeutics, Inc.

Exploring US High Growth Tech Stocks with Promising Potential - Jul 16th, 2025 11:38 am
Soleno sales of new Prader-Willi drug rise faster than expected - Jul 10th, 2025 7:59 am
Sector Update: Health Care Stocks Mixed Premarket Thursday - Jul 10th, 2025 7:21 am
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - Jul 10th, 2025 7:07 am
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - Jul 10th, 2025 4:01 am
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 - Jul 10th, 2025 4:00 am
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 - Jul 1st, 2025 6:00 am
TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy - Jun 26th, 2025 1:24 pm
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Jun 25th, 2025 6:00 am
DoorDash, AMD upgraded: Wall Street's top analyst calls - Jun 23rd, 2025 7:38 am
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects - Jun 20th, 2025 2:04 pm
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Jun 20th, 2025 6:00 am
High Growth Tech Stocks in US for June 2025 - Jun 13th, 2025 11:38 am
EMA validates Soleno’s application for Prader-Willi syndrome treatment - May 26th, 2025 7:16 am
Soleno Therapeutics seeking regulatory approval in treatment of PWS - May 23rd, 2025 3:40 pm
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - May 22nd, 2025 11:55 pm
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - May 22nd, 2025 3:32 pm
Soleno Therapeutics to Participate in Upcoming June Conferences - May 21st, 2025 6:00 am
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome - May 20th, 2025 2:05 pm
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - May 15th, 2025 6:00 am